Equities

Genetic Signatures Ltd

GSS:ASX

Genetic Signatures Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.75
  • Today's Change-0.01 / -1.32%
  • Shares traded1.74k
  • 1 Year change+17.22%
  • Beta-0.2968
Data delayed at least 20 minutes, as of Jul 26 2024 05:33 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx) company. The Company's principal activities include research and commercialization of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces. The Company is focused on the development and commercialization of its platform technology, 3base. Its MDx 3base platform technology provides high-volume hospitals and pathology laboratories with the ability to screen for an array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. It designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen brand. Its products include EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, EasyScreen Viral Meningitis Detection Kit, and others.

  • Revenue in AUD (TTM)16.49m
  • Net income in AUD-18.04m
  • Incorporated2001
  • Employees--
  • Location
    Genetic Signatures LtdHeart Research Institute7 Eliza Street NewtownSYDNEY 2042AustraliaAUS
  • Phone+61 29870-7580
  • Fax+61 29240-9821
  • Websitehttps://geneticsignatures.com/au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
EchoIQ Ltd86.00k-6.41m88.71m----11.90--1,031.55-0.0136-0.01360.00020.01390.0094--1.37---69.93-67.11-79.34-88.25-----7,453.65-925.33----0.00---57.2648.95-27.35--156.99--
SDI Ltd109.61m8.04m108.17m300.0013.451.218.760.98690.06760.06760.92210.74940.84491.696.22--6.207.277.468.4059.2859.797.348.071.2610.370.231851.8513.357.67-3.094.5052.585.39
Imricor Medical Systems Inc941.53k-34.61m117.66m--------124.97-0.2199-0.21990.006-0.07930.05590.87492.38---205.60-93.47-294.49-106.30-181.27-134.71-3,675.60-2,462.890.4944-3.6415.92---24.56-9.29-30.36---10.82--
ImpediMed Ltd10.47m-19.42m133.52m76.00--2.62--12.75-0.0102-0.01020.00550.02520.19611.324.41137,802.60-36.37-52.27-40.94-62.3486.9580.64-185.47-264.766.85--0.0244--7.3627.87-3.26--37.83--
Mach7 Technologies Ltd26.97m-5.55m143.54m90.00--2.6466.325.32-0.0231-0.02310.11230.22560.3605--3.21---7.42-7.48-8.73-8.6595.0993.72-20.59-20.56---2,605.170.0193--10.9728.3074.85--29.28--
Genetic Signatures Ltd16.49m-18.04m169.93m----3.45--10.30-0.1245-0.12450.11360.21720.33661.065.25---36.81-7.14-40.19-7.8240.6657.68-109.38-13.745.95-18,040.000.0003---38.1133.44-558.77--73.20--
EMvision Medical Devices Ltd8.86m-3.22m170.00m----27.17--19.19-0.0449-0.04490.11860.07330.7954-------28.95-67.20-45.25-79.38-----36.40-175.99---35.200.3424--62.0870.4736.64------
Cyclopharm Limited32.21m-4.70m177.82m87.00--4.67--5.52-0.0508-0.05080.34760.34280.67481.114.13370,173.10-9.85-12.60-11.92-14.9468.1570.20-14.60-25.472.32-18.400.1159--11.2215.5028.90---7.83-12.94
Optiscan Imaging Ltd1.68m-5.44m179.60m8.00--10.96--106.90-0.0074-0.00740.00230.01960.1344-0.52531.48---43.54-47.55-50.01-57.08148.555.08-323.87-254.449.43--0.0269--65.86-5.23-2.80---15.27--
4DMedical Ltd1.03m-30.83m211.42m----2.21--206.22-0.0882-0.08820.00290.23320.00980.0920.1585---29.47-43.96-39.07-57.5895.0032.30-3,007.64-2,704.361.79--0.0476---31.84-1.86-27.92--2.46--
Aroa Biosurgery Ltd62.18m-9.57m216.85m261.00--2.54--3.49-0.0278-0.02780.18080.24830.6071.562.82---9.34-10.37-10.11-12.5285.3980.63-15.39-20.316.40--0.0726--9.0124.26-2,583.84--33.65--
Data as of Jul 26 2024. Currency figures normalised to Genetic Signatures Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

35.81%Per cent of shares held by top holders
HolderShares% Held
Perennial Value Management Ltd.as of 13 Jun 202433.48m15.32%
FIL Investment Management (Hong Kong) Ltd.as of 13 Jun 202418.34m8.39%
Regal Funds Management Pty Ltd.as of 13 Jun 202414.53m6.65%
Pengana Capital Ltd.as of 29 Feb 20246.43m2.94%
Norges Bank Investment Managementas of 31 Dec 20234.77m2.18%
DFA Australia Ltd.as of 30 Jun 2024474.02k0.22%
Dimensional Fund Advisors LPas of 30 Apr 2024210.69k0.10%
FIL Investment Advisorsas of 28 Aug 202315.65k0.01%
Dimensional Fund Advisors Ltd.as of 31 May 202410.84k0.01%
More ▼
Data from 31 Jul 2021 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.